August 2007 - Volume 46 - Issue 2 : Hepatology (original) (raw)

August 2007 - Volume 46 - Issue 2

Editor-in-Chief:

Gregory J. Gores

Ranking:

Gastroenterology & Hepatology 7/153

• Editorials

  • Is vitamin E beneficial in chronic liver disease?†‡

  Ingrid Hickman, Graeme Macdonald
  Hepatology. August 2007: 46(2):288-290

  • Ammonia and inflammation in the pathogenesis of hepatic encephalopathy

  Pandora's box?†‡
  Gavin Wright, Rajiv Jalan
  Hepatology. August 2007: 46(2):291-294

  • Determining the model for end‐stage liver disease with better accuracy

  Neutralizing the international normalized ratio pitfalls†‡
  Richard A. Marlar
  Hepatology. August 2007: 46(2):295-296

• Original Articles

  • A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C†

  Hongjin Huang, Mitchell L. Shiffman, Scott Friedman, Ramasubbu Venkatesh, Natalie Bzowej, Olivia T. Abar, Charles M. Rowland, Joseph J. Catanese, Diane U. Leong, John J. Sninsky, Thomas J. Layden, Teresa L. Wright, Thomas White, Ramsey C. Cheung
  Hepatology. August 2007: 46(2):297-306

  • Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection†

  Leonardo L. Schiavon, Janaína N. Schiavon, Roberto J. Carvalho Filho, Juliana P. Sampaio, Valéria P. Lanzoni, Antonio B. Silva, Maria G. Ferraz
  Hepatology. August 2007: 46(2):307-314

  • Oral IDN‐6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C†

  Paul J. Pockros, Eugene R. Schiff, Mitchell L. Shiffman, John G. McHutchison, Robert G. Gish, Nezam H. Afdhal, Manana Makhviladze, Mira Huyghe, David Hecht, Tilman Oltersdorf, David A. Shapiro
  Hepatology. August 2007: 46(2):324-329

  • Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus†

  Eike Steinmann, Thomas Whitfield, Stephanie Kallis, Raymond A. Dwek, Nicole Zitzmann, Thomas Pietschmann, Ralf Bartenschlager
  Hepatology. August 2007: 46(2):330-338

  • Human leukocyte antigen–associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution†

  Joerg Timm, Bin Li, Marcus G. Daniels, Tanmoy Bhattacharya, Laura L. Reyor, Rachel Allgaier, Thomas Kuntzen, Will Fischer, Brian E. Nolan, Jared Duncan, Julian Schulze zur Wiesch, Arthur Y. Kim, Nicole Frahm, Christian Brander, Raymond T. Chung, Georg M. Lauer, Bette T. Korber, Todd M. Allen
  Hepatology. August 2007: 46(2):339-349

  • Selective decrease in hepatitis C virus–specific immunity among African Americans and outcome of antiviral therapy†

  Hugo R. Rosen, Scott J. Weston, KyungAh Im, Huiying Yang, James R. Burton, Henry Erlich, Jared Klarquist, Steven H. Belle
  Hepatology. August 2007: 46(2):350-358

  • Hepatitis C virus quasispecies in HIV‐infected women

  Role of injecting drug use and highly active antiretroviral therapy (HAART)†
  Tomasz Laskus, Jeffrey Wilkinson, Roksana Karim, Wendy Mack, Marek Radkowski, Marina deGiacomo, Jonathan Nasseri, Zhi Chen, Jiaao Xu, Andrea Kovacs
  Hepatology. August 2007: 46(2):359-370

  • Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha†

  Mitchell L. Shiffman, Jennifer Salvatore, Sarah Hubbard, Angie Price, Richard K. Sterling, R. Todd Stravitz, Velimir A. Luketic, Arun J. Sanyal
  Hepatology. August 2007: 46(2):371-379

  • Evidence for a role of nonalcoholic steatohepatitis in hepatitis C

  A prospective study†
  Pierre Bedossa, Rami Moucari, Emna Chelbi, Tarik Asselah, Valerie Paradis, Michel Vidaud, Dominique Cazals‐Hatem, Nathalie Boyer, Dominique Valla, Patrick Marcellin
  Hepatology. August 2007: 46(2):380-387

  • Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis† ‡ §

  Erik J. Buster, Bettina E. Hansen, Maria Buti, Jean Delwaide, Claus Niederau, Peter P. Michielsen, Robert Flisiak, Pieter E. Zondervan, Solko W. Schalm, Harry A. Janssen
  Hepatology. August 2007: 46(2):388-394

  • Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase†

  Chee‐Kin Hui, Nancy Leung, Siu‐Tsan Yuen, Hai‐Ying Zhang, Kar‐Wai Leung, Lei Lu, Stephen F. Cheung, Wai‐Man Wong, George K. Lau
  Hepatology. August 2007: 46(2):395-401

  • X protein of hepatitis B virus functions as a transcriptional corepressor on the human telomerase promoter†

  Jiun‐Ming Su, Xiang‐Me Lai, Keng‐Hsin Lan, Chung‐Pin Li, Yee Chao, Sang‐Hue Yen, Full‐Young Chang, Shou‐Dong Lee, Wei‐Ping Lee
  Hepatology. August 2007: 46(2):402-413

  • Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice†

  Inmaculada García‐Ruiz, Cristina Rodríguez‐Juan, Teresa Díaz‐Sanjuán, Miguel Ángel Martínez, Teresa Muñoz‐Yagüe, José A. Solís‐Herruzo
  Hepatology. August 2007: 46(2):414-423

  • The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†

  Glen Lutchman, Apurva Modi, David E. Kleiner, Kittichai Promrat, Theo Heller, Marc Ghany, Brian Borg, Rohit Loomba, T. Jake Liang, Ahalya Premkumar, Jay H. Hoofnagle
  Hepatology. August 2007: 46(2):424-429

  • Coffee drinking and hepatocellular carcinoma risk

  A meta‐analysis†
  Francesca Bravi, Cristina Bosetti, Alessandra Tavani, Vincenzo Bagnardi, Silvano Gallus, Eva Negri, Silvia Franceschi, Carlo La Vecchia
  Hepatology. August 2007: 46(2):430-435